Kymera Therapeutics to Participate in Upcoming September Investor Conferences
August 28 2024 - 6:00AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing a new class of small molecule
medicines using targeted protein degradation (TPD), today announced
that the Company will participate in fireside chats and
presentations at the following upcoming investor events:
- Wells Fargo 2024 Healthcare Conference in Boston, MA on
September 4 at 3:00 p.m. ET;
- Morgan Stanley 22nd Annual Global Healthcare Conference in New
York, NY on September 5 at 3:20 p.m. ET;
- H.C. Wainwright 26th Annual Global Investment Conference in New
York, NY on September 9 at 8:00 a.m. ET; and
- 2024 Cantor Fitzgerald Global Healthcare Conference in New
York, NY on September 17 at 11:30 a.m. ET.
Live webcasts of the presentations will be available under “News
and Events” in the Investors section of the Company’s website at
www.kymeratx.com. Replays of the webcasts will be archived and
available following the events.
About Kymera TherapeuticsKymera is a
clinical-stage biotechnology company pioneering the field of
targeted protein degradation (TPD) to develop medicines that
address critical health problems and have the potential to
dramatically improve patients’ lives. Kymera is deploying TPD to
address disease targets and pathways inaccessible with conventional
therapeutics. Having advanced the first degrader into the clinic
for immunological diseases, Kymera is focused on delivering oral
small molecule degraders to provide a new generation of convenient,
highly effective therapies for patients with these conditions.
Kymera is also progressing degrader oncology programs that target
undrugged or poorly drugged proteins to create new ways to fight
cancer. Founded in 2016, Kymera has been recognized as one of
Boston’s top workplaces for the past several years. For more
information about our science, pipeline and people, please visit
www.kymeratx.com or follow us on X (previously Twitter) or
LinkedIn.
Investor and Media
Contact:Justine KoenigsbergVice President, Investor
Relationsinvestors@kymeratx.commedia@kymeratx.com857-285-5300 |
|
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Nov 2023 to Nov 2024